|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
1996-7-18
|
|
pubmed:abstractText |
Paclitaxel and cisplatin use for the treatment of advanced ovarian carcinoma (AOC) has been shown to increase median survival duration. An evaluation was performed on the economic consequences of treating AOC patients with combined paclitaxel and cisplatin chemotherapy compared with current usual care, i.e., combined cyclophosphamide and cisplatin chemotherapy.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
77
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2086-91
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:8640674-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:8640674-Cisplatin,
pubmed-meshheading:8640674-Cost-Benefit Analysis,
pubmed-meshheading:8640674-Female,
pubmed-meshheading:8640674-Health Care Costs,
pubmed-meshheading:8640674-Humans,
pubmed-meshheading:8640674-Linear Models,
pubmed-meshheading:8640674-Models, Economic,
pubmed-meshheading:8640674-Ovarian Neoplasms,
pubmed-meshheading:8640674-Paclitaxel,
pubmed-meshheading:8640674-Survival Rate
|
|
pubmed:year |
1996
|
|
pubmed:articleTitle |
Is paclitaxel and cisplatin a cost-effective first-line therapy for advance ovarian carcinoma?
|
|
pubmed:affiliation |
Toronto-Sunnybrook Regional Cancer Center, Toronto, Ontario, Canada.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|
